LYG-202, a Newly Synthesized Flavonoid, Exhibits Potent Anti-angiogenic Activity In Vitro and In Vivo

被引:21
作者
Chen, Yan [1 ]
Lu, Na [1 ]
Ling, Yun [1 ]
Wang, Ling [1 ]
You, Qidong [1 ]
Li, Zhiyu [1 ]
Guo, Qinglong [1 ]
机构
[1] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
flavonoid; angiogenesis; human umbilical vein endothelial cell (HUVEC); vascular endothelial growth factor (VEGF); KDR/Flk-1 (VEGFR-2); ENDOTHELIAL GROWTH-FACTOR; INDUCED TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; VEGF; INHIBITION; MECHANISMS; KDR/FLK-1; RECEPTOR;
D O I
10.1254/jphs.09213FP
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
LYG-202 (C25H30N2O5) is a newly synthesized flavonoid that has been confirmed to possess an antitumor effect, but the mechanism is unclear. Our present study was performed to identify the anti-angiogenic activity of this novel compound in vitro and in vivo. LYG-202 inhibited vascular endothelial growth factor (VEGF) Stimulated migration and tube formation of human umbilical vein endothelial cells and arrested microvessel outgrowth from rat aortic rings in vitro. Meanwhile, LYG-202 suppressed the neovascularization of Chicken Chorioallantoic Membrane in vivo. Mechanistic studies revealed that LYG-202 suppressed the VEGF-induced tyrosine phosphorylation of KDR/Flk-1 (VEGFR-2) as well as its downstream protein kinases activation, by decreasing phosphorylated forms of serine/threonine kinase Akt, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase. LYG-202 exerts anti-angiogenic activity both in vitro and in vivo, and these results suggest that it deserves further investigation as a promising anti-tumor angiogenesis compound.
引用
收藏
页码:37 / 45
页数:9
相关论文
共 38 条
[1]   Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A2 [J].
Ashton, AW ;
Yokota, R ;
John, G ;
Zhao, SM ;
Suadicani, SO ;
Spray, DC ;
Ware, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (50) :35562-35570
[2]   Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders [J].
Autiero, M ;
Luttun, A ;
Tjwa, M ;
Carmeliet, P .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1356-1370
[3]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[4]   Angiogenesis in life, disease and medicine [J].
Carmeliet, P .
NATURE, 2005, 438 (7070) :932-936
[5]   FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [J].
Cross, MJ ;
Claesson-Welsh, L .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) :201-207
[6]  
CUNNINGHAM BDM, 1992, ANTI-CANCER DRUG DES, V7, P365
[7]  
Dulak J, 2005, J Physiol Pharmacol, V56 Suppl 1, P51
[8]   The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25
[9]  
FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
[10]   Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase Akt signal transduction pathway -: Requirement for Flk-1/KDR activation [J].
Gerber, HP ;
McMurtrey, A ;
Kowalski, J ;
Yan, MH ;
Keyt, BA ;
Dixit, V ;
Ferrara, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (46) :30336-30343